Please login to the form below

Kevzara

This page shows the latest Kevzara news and features for those working in and with pharma, biotech and healthcare.

Two drugs found to reduce mortality in severe COVID-19 patients

Actemra and Kevzara also improved recovery times among critically ill COVID-19 patients. ... Both Actemra and Kevzara are IL-6 receptor agonists and are most commonly used to treat anti-inflammatory conditions, including arthritis.

Latest news

Novartis’ canakinumab failed to improve survival in COVID-19 study

This includes Roche’s Actemra (tocilizumab) and Sanofi and Regeneron’s Kevzara (sarilumab), with both drugs entering clinical trials evaluating their efficacy in severely ill COVID-19 patients. ... Kevzara was also unable to prevent death or help
Lilly’s Olumiant combined with Gilead’s remdesivir hits the mark in COVID-19

This includes Sanofi’s Kevzara (sarilumab) and Roche’s Actemra (tocilizumab), although both of these drugs failed their respective studies in COVID-19. ... Despite the disappointing results, Roche is continuing its investigation of Actemra in severe
AbbVie, Amgen and Takeda team up for joint COVID-19 trial

A number of other anti-inflammatory drugs have also failed to hit the mark in COVID-19, including Sanofi/Regeneron’s rheumatoid arthritis drug Kevzara (sarilumab) and Roche’s Actemra (tocilizumab).
Roche’s Actemra fails in late-stage severe COVID-19 study

Sanofi/Regeneron’s IL-6 inhibitor Kevzara (sarilumab) was also unable to prevent death or help patients come off ventilation among mechanically ventilated patients. ... remdesivir. The Swiss pharma company is also evaluating Kevzara in
Regeneron’s COVID-19 antibody cocktail enters phase 3 trial

The progress of REGN-COV2 is welcome news for Regeneron, after it had to abandon its Sanofi-partnered study of Kevzara (sarilumab) following disappointing results in a phase 3 trial. ... With Kevzara falling by the wayside, Regeneron is now pinning its

More from news
Approximately 6 fully matching, plus 24 partially matching documents found.

Latest Intelligence

As COVID-19 takes over the world, biopharma fights back

Evaluating IL-6 inhibitors: Roche’s Actemra and Sanofi and Regeneron’s Kevzara. Roche, Sanofi and Regeneron are also looking to repurpose their existing treatments and are currently testing their ... Encouraged by this initial data, Sanofi and

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Account Director – Creative Healthcare Communications: Competative

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Healthcare Senior Account Manager: Competitive

Medical Editor: Competitive

Healthcare Account Director: Competitive

Healthcare Lead Copywriter: Competitive

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

PMHub

Add my company

Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

AstraZeneca’s focus on diagnosing and managing chronic kidney disease: People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story: How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
Three ways AI will change healthcare in the next decade: Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...